Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Prevalence of ongoing or previous SARS-CoV-2 infection among dental personnel - the Swedish experience.

Authors:
Lars Fredriksson Andreas Cederlund My Murray Leif Jansson Pia Skott

Acta Odontol Scand 2022 Jun 30:1-5. Epub 2022 Jun 30.

Folktandvården Stockholm, Public Dental Services, Stockholm County Council, Stockholm, Sweden.

Objective: To investigate whether personnel in a public dental clinic had a higher frequency of ongoing or previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than hospital healthcare workers or the general public in Stockholm during weeks 23-25 in 2020.

Materials And Methods: We carried out an observational cohort study from March to June 2020, including 341 employees randomly selected from Public Dental Service in the County of Stockholm. The primary outcome variable was the prevalence of SARS-CoV-2 RNA and/or antibodies against SARS-CoV-2. Throat samples were analysed for SARS-CoV-2 RNA. Venous blood was collected to detect antibodies against SARS-CoV-2 using the Luminex analysis tool (immunoassay) and ELISA. Logistic regression analysis was used to compare the independent groups and calculate the unadjusted odds ratio.

Results: The mean age of the participants was 50.1 years, and 11.7% were male. The prevalence of SARS-CoV-2 RNA and/or antibodies against SARS-CoV-2 was 12.0% (95% confidence interval 8.8-16.0). Among them, 82.5% reported symptoms and 85.4% were on sick-leave between March and June 2020.

Conclusions: The seroprevalence of SARS-CoV-2 infection was approximately similar to that in healthcare personnel, and approximately equal compared to that in the general population.

Download full-text PDF

 Source
http://dx.doi.org/10.1080/00016357.2022.2095023DOI Listing
June 2022

Publication Analysis

Top Keywords

antibodies sars-cov-2
12
sars-cov-2 rna
12
sars-cov-2 infection
12
sars-cov-2
9
prevalence sars-cov-2
8
public dental
8
rna and/or
8
and/or antibodies
8
march june
8
ongoing previous
8
infection healthcare
4
luminex analysis
4
sars-cov-2 luminex
4
detect antibodies
4
collected detect
4
blood collected
4
venous blood
4
rna venous
4
analysed sars-cov-2
4
samples analysed
4

Keyword Occurance

Similar Publications

Covid-19 vaccination in pregnancy.

Authors:
Martina L Badell Carolynn M Dude Sonja A Rasmussen Denise J Jamieson

BMJ 2022 Aug 10;378:e069741. Epub 2022 Aug 10.

Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA. USA.

Pregnancy is an independent risk factor for severe covid-19. Vaccination is the best way to reduce the risk for SARS-CoV-2 infection and limit its morbidity and mortality. The current recommendations from the World Health Organization, Centers for Disease Control and Prevention, and professional organizations are for pregnant, postpartum, and lactating women to receive covid-19 vaccination. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques.

Authors:
Wan-Ting He Meng Yuan Sean Callaghan Rami Musharrafieh Ge Song Murillo Silva Nathan Beutler Wen-Hsin Lee Peter Yong Jonathan L Torres Mariane Melo Panpan Zhou Fangzhu Zhao Xueyong Zhu Linghang Peng Deli Huang Fabio Anzanello James Ricketts Mara Parren Elijah Garcia Melissa Ferguson William Rinaldi Stephen A Rawlings David Nemazee Davey M Smith Bryan Briney Yana Safonova Thomas F Rogers Jennifer M Dan Zeli Zhang

Sci Transl Med 2022 Aug 10;14(657):eabl9605. Epub 2022 Aug 10.

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

To prepare for future coronavirus (CoV) pandemics, it is desirable to generate vaccines capable of eliciting broadly neutralizing antibody responses to CoVs. Here, we show that immunization of macaques with SARS-CoV-2 spike (S) protein with a two-shot protocol generated potent serum receptor binding domain cross-neutralizing antibody responses to both SARS-CoV-2 and SARS-CoV-1. Furthermore, responses were equally effective against most SARS-CoV-2 variants of concern (VOCs) and some were highly effective against Omicron. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.

Authors:
Ying Fu Juliana da Fonseca Rezende E Mello Bryan D Fleming Alex Renn Catherine Z Chen Xin Hu Miao Xu Kirill Gorshkov Quinlin Hanson Wei Zheng Emily M Lee Lalith Perera Robert Petrovich Manisha Pradhan Richard T Eastman Zina Itkin Thomas B Stanley Allen Hsu Venkata Dandey Kedar Sharma William Gillette Troy Taylor Nitya Ramakrishnan Shelley Perkins Dominic Esposito Eunkeu Oh Kimihiro Susumu Mason Wolak Marc Ferrer Matthew D Hall

PLoS One 2022 10;17(8):e0272364. Epub 2022 Aug 10.

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

Neutralizing antibodies targeting the SARS-CoV-2 spike protein have shown a great preventative/therapeutic potential. Here, we report a rapid and efficient strategy for the development and design of SARS-CoV-2 neutralizing humanized nanobody constructs with sub-nanomolar affinities and nanomolar potencies. CryoEM-based structural analysis of the nanobodies in complex with spike revealed two distinct binding modes. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway.

Authors:
Marjut Sarjomaa Lien My Diep Chi Zhang Yngvar Tveten Harald Reiso Carina Thilesen Svein Arne Nordbø Kristine Karlsrud Berg Ingeborg Aaberge Neil Pearce Hege Kersten Jan Paul Vandenbroucke Randi Eikeland Anne Kristin Møller Fell

PLoS One 2022 10;17(8):e0264667. Epub 2022 Aug 10.

Department of Community Medicine and Global Health and Society, University of Oslo, Oslo, Norway.

Objectives: To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals and the possible predictors of antibody persistence.

Methods: This is the first part of a prospective multi-centre cohort study.

Participants: The study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative participants in South-Eastern Norway from February to December 2020. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.

Authors:
C Sabrina Tan Ai-Ris Y Collier Jingyou Yu Jinyan Liu Abishek Chandrashekar Katherine McMahan Catherine Jacob-Dolan Xuan He Vicky Roy Blake M Hauser Jennifer E Munt Michael L Mallory Melissa Mattocks John M Powers Rita M Meganck Marjorie Rowe Rachel Hemond Esther A Bondzie Kate H Jaegle Ralph S Baric Aaron G Schmidt Galit Alter Mathieu Le Gars Jerald Sadoff Dan H Barouch

JAMA Netw Open 2022 Aug 1;5(8):e2226335. Epub 2022 Aug 1.

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Importance: Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting.

Objective: To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}